2,248 results on '"Müller-Tidow, Carsten"'
Search Results
2. Circulating tumor cell plasticity determines breast cancer therapy resistance via neuregulin 1–HER3 signaling
3. Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myeloma
4. Single-cell multiomics analysis reveals dynamic clonal evolution and targetable phenotypes in acute myeloid leukemia with complex karyotype
5. Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic leukemia: a phase 1/2 study
6. The landscape of RNA-chromatin interaction reveals small non-coding RNAs as essential mediators of leukemia maintenance
7. Multiple myeloma long-term survivors exhibit sustained immune alterations decades after first-line therapy
8. Proteasome inhibition enhances the anti-leukemic efficacy of chimeric antigen receptor (CAR) expressing NK cells against acute myeloid leukemia
9. Longitudinal assessment of established risk stratification models in patients with monoclonal gammopathy of undetermined significance
10. Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence
11. DNMT3A clonal hematopoiesis-driver mutations induce cardiac fibrosis by paracrine activation of fibroblasts
12. CD8+ CD28− regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study
13. Molecular subgroups of T-cell acute lymphoblastic leukemia in adults treated according to pediatric-based GMALL protocols
14. Multimodal and spatially resolved profiling identifies distinct patterns of T cell infiltration in nodal B cell lymphoma entities
15. Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients
16. Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies: the prospective non-interventional SMARTrial
17. High-throughput electron tomography identifies centriole over-elongation as an early event in plasma cell disorders
18. The landscape of small nucleolar RNA expression in multiple myeloma is determined by cytogenetic alterations
19. Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia
20. Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification
21. Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experience
22. The ribosomal protein S6 kinase alpha-1 (RPS6KA1) induces resistance to venetoclax/azacitidine in acute myeloid leukemia
23. Targeted siRNA nanocarrier: a platform technology for cancer treatment
24. Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
25. Human and mouse neutrophils share core transcriptional programs in both homeostatic and inflamed contexts
26. Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials
27. Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level
28. First third-generation CAR T cell application targeting CD19 for the treatment of systemic IgM AL amyloidosis with underlying marginal zone lymphoma
29. Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD
30. Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial
31. UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome
32. Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles
33. Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome
34. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy
35. Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study
36. Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial
37. Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML
38. Cure of intravascular NK/T-cell lymphoma of the central nervous system by allogeneic hematopoietic cell transplantation
39. Mini‐consolidations or intermediate‐dose cytarabine for the post‐remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries.
40. GVHD after CAR T-cell therapy post allogeneic hematopoietic cell transplantation — successfully treated by extracorporeal photopheresis.
41. Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries
42. Correlation of nutrition-associated parameters with non-relapse mortality in allogeneic hematopoietic stem cell transplantation
43. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation
44. Proteogenomics refines the molecular classification of chronic lymphocytic leukemia
45. Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations
46. Electrostatic anti-CD33-antibody–protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia
47. Mini-consolidations or intermediate-dose cytarabine (IDAC) for the post-remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries.
48. Fat aspiration for minimally-invasive amyloidosis screening from an external amyloidosis clinic
49. Stem cell collection in AL patients after different induction and mobilization therapies
50. A Platform for Federated Acquisition of Health-related Quality of Life Data in Systemic Amyloidosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.